ABIVAX
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
ABVX | PA
Overview
Corporate Details
- ISIN(s):
- FR0012333284 (+1 more)
- LEI:
- 969500D8TMNB184OJU95
- Country:
- France
- Address:
- 7 BOULEVARD HAUSSMANN, 75009 PARIS
- Website:
- https://www.abivax.com
- Sector:
- Manufacturing
Description
Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2020-11-19 18:00 |
ABIVAX: Nombre d'actions composant le capital social et nombre total de droits …
|
French | PDF • 277.1 KB | ||
| 2020-11-16 18:30 |
ABIVAX: Abivax recoit le 'Best Technology Award' aux European Mediscience Award…
|
French | PDF • 213.8 KB | ||
| 2020-11-16 18:30 |
Abivax Receives 'Best Technology Award' at the European Mediscience Awards 2020
|
English | HTML • 13.3 KB | ||
| 2020-11-02 14:00 |
Abivax annonce une présentation en webcast et téléconférence suite à l'annonce …
|
French | PDF • 144.9 KB | ||
| 2020-11-02 14:00 |
Abivax announces webcast and teleconference following recent oversubscribed cap…
|
English | HTML • 6.9 KB | ||
| 2020-10-29 08:01 |
Abivax announces the success of its oversubscribed capital increase of EUR 28m …
|
English | HTML • 37.9 KB | ||
| 2020-10-29 07:00 |
Abivax annonce le succès de son augmentation de capital sursouscrite de 28 mill…
|
French | PDF • 295.1 KB | ||
| 2020-10-20 18:00 |
ABIVAX: Nombre d'actions composant le capital social et nombre total de droits …
|
French | PDF • 275.9 KB | ||
| 2020-10-13 08:00 |
Abivax obtient un financement non-dilutif de 15 millions d'euros auprès de Kreo…
|
French | PDF • 249.6 KB | ||
| 2020-10-13 08:00 |
Abivax secures EUR 15m non-dilutive financing from Kreos Capital
|
English | HTML • 13.9 KB | ||
| 2020-09-30 18:19 |
ABIVAX: Rapport Financier Semestriel 2020.
|
French | PDF • 1.0 MB | ||
| 2020-09-30 18:19 |
ABIVAX: Half-Year Financial Report 2020.
|
English | PDF • 909.0 KB | ||
| 2020-09-30 18:00 |
ABIVAX: Abivax annonce la mise à disposition de son rapport financier semestrie…
|
French | PDF • 128.5 KB | ||
| 2020-09-30 18:00 |
Abivax announces the release of its 2020 half-year financial report
|
English | HTML • 6.5 KB | ||
| 2020-09-24 20:00 |
Abivax présente ses résultats semestriels 2020 et fait un point d'avancement s…
|
French | PDF • 386.8 KB |
Automate Your Workflow. Get a real-time feed of all ABIVAX filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABIVAX
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABIVAX via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-11 | N/A | Other | Buy | 319,107 | N/A |
| 2024-03-01 | N/A | Other | Buy | 7,000 | 91,557.90 EUR |
| 2023-12-19 | N/A | Other | Sell | 50,000 | 482,500.00 EUR |
| 2023-12-11 | N/A | Other | Sell | 2,062 | 19,382.80 EUR |
| 2023-11-13 | N/A | Other | Buy | 4 | 39.84 EUR |
| 2023-07-13 | N/A | Other | Sell | 192,781 | 3,101,480.01 EUR |
| 2023-03-27 | N/A | Other | Other | 38,461 | 249,996.50 EUR |
| 2023-02-27 | N/A | Other | Other | 1,535,000 | 9,977,500.00 EUR |
Peer Companies
